

BAXTER INTERNATIONAL INC.
Net Sales
Periods Ending March 31, 2008 and 2007
(unaudited)
(\$ in millions)

	Q1 2008	Q1 2007	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience ¹				
United States	\$547	\$484	13%	13%
International	663	588	13%	3%
Total	\$1,210	\$1,072	13%	8%
Medication Delivery				
United States	\$503	\$515	(2%)	(2%)
International	562	475	18%	8%
Total	\$1,065	\$990	8%	2%
Renal				
United States	\$98	\$97	1%	1%
International	460	428	7%	(2%)
Total	\$558	\$525	6%	(2%)
Baxter excluding Transfusion Therapies				
United States	\$1,148	\$1,096	5%	5%
International	1,685	1,491	13%	3%
Total	\$2,833	\$2,587	10%	4%
Transfusion Therapies ²				
United States	\$31	\$43	(28%)	(28%)
International	13	45	(71%)	(73%)
Total	\$44	\$88	(50%)	(51%)
Baxter International Inc.				
United States	\$1,179	\$1,139	4%	4%
International	1,698	1,536	11%	1%
Total	\$2,877	\$2,675	8%	2%

¹ Prior year BioScience sales data has been reclassified as described in Note 2.

² The Transfusion Therapies (TT) business was sold on February 28, 2007. The results of operations of the TT business were previously reported in the BioScience business. The TT totals above include sales of TT products through the date of divestiture, as well as revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business post-divestiture.